Aptinyx Inc (NASDAQ:APTX) Expected to Post Earnings of -$0.52 Per Share

Equities research analysts expect Aptinyx Inc (NASDAQ:APTX) to announce ($0.52) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aptinyx’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.57). Aptinyx posted earnings of ($1.83) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 71.6%. The company is expected to announce its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Aptinyx will report full year earnings of ($2.21) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.09). For the next financial year, analysts expect that the company will post earnings of ($2.09) per share, with EPS estimates ranging from ($2.31) to ($1.79). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $1.00 million.

Several analysts recently issued reports on the company. Cowen reiterated a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Tuesday. BMO Capital Markets increased their price objective on Alimentation Couche-Tard from C$79.00 to C$84.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Finally, Svb Leerink assumed coverage on Aptinyx in a report on Thursday, June 20th. They set an “outperform” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Aptinyx has a consensus rating of “Buy” and an average price target of $12.71.

Shares of NASDAQ:APTX traded down $0.05 during midday trading on Friday, hitting $3.72. 108,585 shares of the stock were exchanged, compared to its average volume of 317,753. Aptinyx has a 52-week low of $2.88 and a 52-week high of $32.25. The stock’s fifty day moving average is $3.40. The company has a market cap of $126.53 million and a P/E ratio of -1.41.

In related news, Director Henry O. Gosebruch bought 100,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The shares were bought at an average cost of $3.86 per share, for a total transaction of $386,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.47% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Aptinyx during the fourth quarter valued at about $266,000. Bank of New York Mellon Corp raised its holdings in Aptinyx by 30.6% during the fourth quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock valued at $726,000 after buying an additional 10,284 shares in the last quarter. BlackRock Inc. raised its holdings in Aptinyx by 50.2% during the fourth quarter. BlackRock Inc. now owns 1,155,090 shares of the company’s stock valued at $19,105,000 after buying an additional 386,018 shares in the last quarter. Rhumbline Advisers raised its holdings in Aptinyx by 71.0% during the fourth quarter. Rhumbline Advisers now owns 16,944 shares of the company’s stock valued at $280,000 after buying an additional 7,033 shares in the last quarter. Finally, Partner Fund Management L.P. grew its position in shares of Aptinyx by 5.6% in the fourth quarter. Partner Fund Management L.P. now owns 1,852,132 shares of the company’s stock valued at $30,634,000 after purchasing an additional 97,453 shares during the last quarter. Institutional investors own 58.37% of the company’s stock.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: Neutral Rating

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.